Ph.D., Cornell University, Biometry, 1990.
My statistical methods research, in conjunction with colleagues and students, aims to improve the design and analysis of disease prevention trials, and observational studies. One emphasis has been the development of efficient design and analysis strategies for group randomized trials. Recent efforts include the proposal of a weighted permutation inference and a global test for multiple endpoints. Another emphasis has been the development of methods for cancer biomarker studies. Recent efforts include the development of guidelines for biomarker evaluation in cancer early detection, analysis methods for high dimensional data such as protein expression data from mass spectrometry, and Finite Mixture Models.
My applied research, in conjunction with colleagues and staff members, include the coordination of the national Early Detection Research Network (EDRN). This network includes 31 institutions in US with the mission to identify and validate biomarkers for early detection of cancer. We at FHCRC provide logistic, bioinformatics, and data management support for EDRN, and develop statistical methodology useful for EDRN mission.
I also collaborate with a large number of colleagues on variety of research projects including prostate cancer epidemiology and outcome, GI cancer etiology and biomarkers, community intervention trials, and occupational epidemiology.
(Reading, Writing, Speaking)
Chinese, Mandarin: (Fluent, Fluent, Fluent)
English: (Fluent, Fluent, Fluent)
American Statistical Association
Honors and Awards
1990, Cornell Graduate School Fellowship,
1988-1989, Cornell Outstanding Teaching Assistant Award,
1984, Cornell Graduate School Liu Memorial Award,
1997-2003, Affiliate Associate Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
1996-2001, Associate Member, Fred Hutchinson Cancer Research Center, Cancer Prevention Research
1990-1997, Affiliate Assistant Professor, University of Washington, School of Public Health and Community Medicine, Biostatistics
1990-1996, Assistant Member, Fred Hutchinson Cancer Research Center, Cancer Prevention Research
Serum glycans as risk markers for non-small cell lung cancer.. Cancer prevention research (Philadelphia, Pa.).. 2016.
Outcomes of active surveillance for the management of clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort.. The Journal of urology. 195(2):313–320.. 2016.
MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas.. Cancer prevention research (Philadelphia, Pa.).. 2015.
The Net Reclassification Index (NRI): a Misleading Measure of Prediction Improvement Even with Independent Test Data Sets.. Statistics in biosciences. 7(2):282-295.. 2015.
Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(33):3880-3886.. 2015.
Two-stage biomarker panel study and estimation allowing early termination for futility.. Biostatistics (Oxford, England).. 2015.
Confirmation of genetic variants associated with lethal prostate cancer in a cohort of men from hereditary prostate cancer families.. International journal of cancer. Journal international du cancer. 136(9):2166-71.. 2015.
Toward Rigorous Data Harmonization in Cancer Epidemiology Research: One Approach.. American journal of epidemiology. 182(12):1033-8.. 2015.
Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.. The Prostate. 75(16):1941-50.. 2015.
Associations of Body Mass Index, Smoking, and Alcohol Consumption With Prostate Cancer Mortality in the Asia Cohort Consortium.. American journal of epidemiology.. 2015.
Improving the Quality of Biomarker Discovery Research: The Right Samples and Enough of Them.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2015.
Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 24(4):677-82.. 2015.
Methylation analysis in spontaneous sputum for lung cancer diagnosis.. Lung cancer (Amsterdam, Netherlands).. 2014.
Can urinary PCA3 supplement PSA in the early detection of prostate cancer? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(36):4066-72.. 2014.
Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2014.
LOGISTIC REGRESSION ANALYSIS WITH STANDARDIZED MARKERS.. The annals of applied statistics. 7(3). 2013.
Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis.. Cancer epidemiology. 37(5):666-70.. 2013.
Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(9):2442-2450.. 2013.
Health beliefs associated with cervical cancer screening among vietnamese americans.. Journal of women's health (2002). 22(3):276-88.. 2013.
Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy.. Proteomics. Clinical applications. 7(5-6):327-336.. 2013.